Canaccord Genuity Maintains a 'Buy' on Vascular Solutions (VASC); Mixed Q3 and Underwhelming Guidance
Tweet
Share
E-mailGet Alerts VASC Hot Sheet
Price: $56.00 --0%
Rating Summary:
0 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
0 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Vascular Solutions (NASDAQ: VASC), price target cut $1 to $14.50.
Canaccord analyst, Jason R. Mills, said, "Q3 results were disappointing with revenue light and EPS modestly above our estimates with the help of a 2-cent one-timer. GuideLiner again led growth and should continue to do so going forward with the launch of a 2.0 version in Q4/11. Our thesis is unchanged –notwithstanding underwhelming guidance and lower forward estimates – as we continue to see a business model both delivering and primed for OM leverage, and one that has the propensity to layer on tuck-in acquisitions to augment growth/margins. Initial 2012 revenue guidance for 9% growth is underwhelming, albeit decent relative to a sluggish broad med-tech market at present. VASC continues to generate cash and has a solid B/S."
For more ratings news on Vascular Solutions click here and for the rating history of Vascular Solutions click here.
Shares of Vascular Solutions closed at $11.79 yesterday.
Canaccord analyst, Jason R. Mills, said, "Q3 results were disappointing with revenue light and EPS modestly above our estimates with the help of a 2-cent one-timer. GuideLiner again led growth and should continue to do so going forward with the launch of a 2.0 version in Q4/11. Our thesis is unchanged –notwithstanding underwhelming guidance and lower forward estimates – as we continue to see a business model both delivering and primed for OM leverage, and one that has the propensity to layer on tuck-in acquisitions to augment growth/margins. Initial 2012 revenue guidance for 9% growth is underwhelming, albeit decent relative to a sluggish broad med-tech market at present. VASC continues to generate cash and has a solid B/S."
For more ratings news on Vascular Solutions click here and for the rating history of Vascular Solutions click here.
Shares of Vascular Solutions closed at $11.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
